<DOC>
	<DOC>NCT02671682</DOC>
	<brief_summary>This observational study investigates the efficacy and safety of immunoadsorption versus plasmapheresis in 60 patients with relapse in Multiple Sclerosis and Clinically isolated syndrome who do not fully recover after a high doses of intravenous corticosteroids.</brief_summary>
	<brief_title>Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>relapse of Multiple Sclerosis or Clinically Isolated Syndrome (without complete remission after high dose steroid therapy) informed consent age â‰¥ 12 years old clinical or laboratory signs of infection intake of Angiotensin Converting Enzyme Inhibitor within 1 week prior to first treatment</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Immunoadsorption</keyword>
	<keyword>Plasmapheresis</keyword>
</DOC>